Stoke Therapeutics (NASDAQ:STOK) Releases Quarterly Earnings Results, Misses Expectations By $0.22 EPS

Stoke Therapeutics (NASDAQ:STOK) posted its quarterly earnings data on Monday. The company reported ($0.97) earnings per share for the quarter, missing the consensus estimate of ($0.75) by ($0.22), FiscalAI reports. Stoke Therapeutics had a return on equity of 13.28% and a net margin of 19.73%.The firm had revenue of $1.40 million for the quarter, compared to analyst estimates of $5.32 million.

Stoke Therapeutics Trading Up 2.3%

NASDAQ STOK traded up $0.77 on Monday, hitting $33.96. 554,702 shares of the company were exchanged, compared to its average volume of 751,904. The company has a market cap of $1.94 billion, a PE ratio of 50.69 and a beta of 1.07. The stock has a fifty day moving average of $32.71 and a 200-day moving average of $29.70. Stoke Therapeutics has a 12 month low of $5.35 and a 12 month high of $40.22.

Analyst Ratings Changes

A number of brokerages have commented on STOK. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Stoke Therapeutics in a research report on Monday, December 29th. Wedbush lifted their price objective on Stoke Therapeutics from $32.00 to $36.00 and gave the stock an “outperform” rating in a research report on Monday, January 12th. HC Wainwright boosted their price objective on Stoke Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Chardan Capital upped their target price on Stoke Therapeutics from $24.00 to $35.00 and gave the company a “buy” rating in a research report on Monday, January 5th. Finally, Canaccord Genuity Group raised their target price on Stoke Therapeutics from $28.00 to $36.00 and gave the stock a “buy” rating in a research note on Monday, January 5th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Stoke Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $39.25.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Arthur Tzianabos sold 4,355 shares of the stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $40.00, for a total transaction of $174,200.00. Following the transaction, the insider owned 31,339 shares of the company’s stock, valued at $1,253,560. This represents a 12.20% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Adrian R. Krainer sold 33,243 shares of the firm’s stock in a transaction dated Tuesday, March 10th. The shares were sold at an average price of $39.74, for a total value of $1,321,076.82. Following the completion of the sale, the director owned 283,302 shares of the company’s stock, valued at approximately $11,258,421.48. This represents a 10.50% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 9.50% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Stoke Therapeutics by 5.0% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,167 shares of the company’s stock worth $162,000 after acquiring an additional 1,149 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Stoke Therapeutics by 21.4% during the first quarter. Goldman Sachs Group Inc. now owns 1,662,039 shares of the company’s stock valued at $11,053,000 after acquiring an additional 293,072 shares in the last quarter. Jane Street Group LLC increased its holdings in shares of Stoke Therapeutics by 125.2% during the first quarter. Jane Street Group LLC now owns 26,978 shares of the company’s stock valued at $179,000 after acquiring an additional 15,001 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of Stoke Therapeutics by 26.6% during the second quarter. JPMorgan Chase & Co. now owns 25,655 shares of the company’s stock worth $291,000 after purchasing an additional 5,398 shares during the period. Finally, Rhumbline Advisers lifted its holdings in shares of Stoke Therapeutics by 33.9% in the 2nd quarter. Rhumbline Advisers now owns 66,419 shares of the company’s stock worth $754,000 after purchasing an additional 16,820 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.